retatrutide release date FDA Approval Status: July 2026 Update Eli Lilly to release data

Zepbound has a unique mechanism, which involves mimicking two hormones, GLP-1 and GIP, which sets it apart from other weight loss medications

If you experience any unusual symptoms or feel unwell after using such products, contact your GP or NHS 111 for advice

Discuss with your healthcare provider before starting any weight loss programme, supplement, or medication whilst breastfeeding

Either way, considering the cost of these medications and the prevalence of both diabetes or obesity within a population, there is a potential for significant costs for the payers employers, employees or health insurance companies

Safety is unknown

Employers can also require documentation of failed attempts at weight loss through lifestyle modification, participation in medically supervised weight management programs, or trial of less expensive weight loss medications before approving GLP-1 coverage